AAAAAA
Results: 1-25/38
Authors:
Bieche, I
Franc, B
Vidaud, D
Vidaud, M
Lidereau, R
Citation: I. Bieche et al., Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction, THYROID, 11(2), 2001, pp. 147-152
Authors:
Bieche, I
Parfait, B
Laurendeau, I
Girault, I
Vidaud, M
Lidereau, R
Citation: I. Bieche et al., Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer, ONCOGENE, 20(56), 2001, pp. 8109-8115
Authors:
Bieche, I
Parfait, B
Nogues, C
Andrieu, C
Vidaud, D
Spyratos, F
Lidereau, R
Vidaud, M
Citation: I. Bieche et al., The CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients, ONCOGENE, 20(47), 2001, pp. 6955-6959
Authors:
Jacquemier, J
Lidereau, R
Birnbaum, D
Eisinger, F
Sobol, H
Citation: J. Jacquemier et al., Assessing the risk of BRCA1-associated breast cancer using individual morphological criteria, HISTOPATHOL, 38(4), 2001, pp. 378-379
Authors:
Bieche, I
Onody, P
Lerebours, F
Tozlu, S
Hacene, K
Andrieu, C
Vidaud, M
Tubiana-Hulin, M
Spyratos, F
Lidereau, R
Citation: I. Bieche et al., ERBB2 status and benefit from adjuvant tamoxifen in ER alpha-positive postmenopausal breast carcinoma, CANCER LETT, 174(2), 2001, pp. 173-178
Authors:
Giovangrandi, Y
Parfait, B
Asheuer, M
Olivi, M
Lidereau, R
Vidaud, M
Bieche, I
Citation: Y. Giovangrandi et al., Analysis of the human CGB/LHB gene cluster in breast tumors by real-time quantitative RT-PCR assays, CANCER LETT, 168(1), 2001, pp. 93-100
Authors:
Bieche, I
Parfait, A
Tozlu, S
Lidereau, R
Vidaud, M
Citation: I. Bieche et al., Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene, CARCINOGENE, 22(9), 2001, pp. 1521-1526
Authors:
Bertheau, P
Plassa, LF
Lerebours, F
de Roquancourt, A
Turpin, E
Lidereau, R
de The, H
Janin, A
Citation: P. Bertheau et al., Allelic loss detection in inflammatory breast cancer: Improvement with laser microdissection, LAB INV, 81(10), 2001, pp. 1397-1402
Authors:
Latil, A
Bieche, I
Vidaud, D
Lidereau, R
Berthon, P
Cussenot, O
Vidaud, M
Citation: A. Latil et al., Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays, CANCER RES, 61(5), 2001, pp. 1919-1926
Authors:
Bieche, I
Parfait, B
Le Doussal, V
Olivi, M
Rio, MC
Lidereau, R
Vidaud, M
Citation: I. Bieche et al., Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: An outstanding candidate marker to predict the response to endocrine therapy, CANCER RES, 61(4), 2001, pp. 1652-1658
Authors:
Onody, P
Bertrand, F
Muzeau, F
Bieche, I
Lidereau, R
Citation: P. Onody et al., Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination - Application to node-negative breast cancer, ARCH PATH L, 125(6), 2001, pp. 746-750
Authors:
de Pinieux, G
Legrier, ME
Poirson-Bichat, F
Courty, Y
Bras-Goncalves, R
Dutrillaux, AM
Nemati, F
Oudard, S
Lidereau, R
Broqua, P
Junien, JL
Dutrillaux, B
Poupon, MF
Citation: G. De Pinieux et al., Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach, AM J PATH, 159(2), 2001, pp. 753-764
Authors:
Bieche, I
Nogues, C
Paradis, V
Olivi, R
Bedossa, P
Lidereau, R
Vidaud, M
Citation: I. Bieche et al., Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay, CLIN CANC R, 6(2), 2000, pp. 452-459
Authors:
Bieche, I
Lidereau, R
Citation: I. Bieche et R. Lidereau, Loss of heterozygosity at 13q14 correlates with RB1 cone underexpression in human breast cancer, MOL CARCINO, 29(3), 2000, pp. 151-158
Authors:
Spyratos, F
Andrieu, C
Vidaud, D
Briffod, M
Vidaud, M
Lidereau, R
Bieche, I
Citation: F. Spyratos et al., CCND1 mRNA overexpression is highly related to estrogen receptor positivity but not to proliferative markers in primary breast cancer, INT J B MAR, 15(3), 2000, pp. 210-214
Authors:
Latil, A
Bieche, I
Pesche, S
Valeri, A
Fournier, G
Cussenot, O
Lidereau, R
Citation: A. Latil et al., VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms, INT J CANC, 89(2), 2000, pp. 167-171
Authors:
Latil, A
Vidaud, D
Valeri, A
Fournier, G
Vidaud, M
Lidereau, R
Cussenot, O
Bieche, I
Citation: A. Latil et al., htert expression correlates with myc over-expression in human prostate cancer, INT J CANC, 89(2), 2000, pp. 172-176
Authors:
Lidereau, R
Eisinger, F
Champeme, MH
Nogues, C
Bieche, I
Birnbaum, D
Pallud, C
Jacquemier, J
Sobol, H
Citation: R. Lidereau et al., Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer, CANCER RES, 60(5), 2000, pp. 1206-1210
Authors:
Curmi, PA
Nogues, C
Lachkar, S
Carelle, N
Gonthier, MP
Sobel, A
Lidereau, R
Bieche, I
Citation: Pa. Curmi et al., Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours, BR J CANC, 82(1), 2000, pp. 142-150
Authors:
Mazoyer, S
Leary, J
Kirk, J
Fleischmann, E
Wagner, T
Claes, K
Messiaen, L
Foulkes, W
Desrochers, M
Simard, J
Phelan, CM
Kwan, E
Narod, SA
Vahteristo, P
Nevanlinna, H
Durando, X
Bignon, YJ
Peyrat, JP
Bonnardel, C
Sinilnikova, OM
Puget, N
Lenoir, GM
Mazoyer, S
Audoynaud, C
Goldgar, D
Maugard, C
Caux, V
Gad, S
Stoppa-Lyonnet, D
Nogues, C
Lidereau, R
Machavoine, C
Bressac-de Paillerets, B
Kuschel, B
Betz, B
Niederacher, D
Beckmann, MW
Hamann, U
Gayther, SA
Ponder, BAP
Robinson, M
Taylor, GR
Bishop, T
Catteau, A
Solomon, E
Cohen, B
Steel, M
Collins, N
Stratton, M
van der Looij, M
Olah, E
Miller, NJ
Barton, DE
Sverdlov, RS
Friedman, E
Radice, P
Montagna, M
Sensi, E
Caligo, M
van Eijk, R
Devilee, P
van der Luijt, R
Heimdal, K
Moller, P
Borg, A
Diez, O
Cortes, J
Domenech, M
Baiget, M
Osorio, A
Benitez, J
Borg, A
Maillet, P
Sappino, AP
Ozdag, H
Ozcelik, T
Ozturk, M
Rohlfs, EM
Boyd, J
McDermott, D
Offit, K
Unger, M
Nathanson, K
Weber, BL
Sellers, TA
Hampton, E
Couch, FJ
Neuhausen, S
Citation: S. Mazoyer et al., The exon 13 duplication in the BRCA1 gene is a founder mutation present ingeographically diverse populations, AM J HU GEN, 67(1), 2000, pp. 207-212
Authors:
Laake, K
Launonen, V
Niederacher, D
Gudlaugsdottir, S
Seitz, S
Rio, P
Champeme, MH
Bieche, I
Birnbaum, D
White, G
Sztan, M
Sever, N
Plummer, S
Osorio, A
Broeks, A
Huusko, P
Spurr, N
Borg, A
Cleton-Jansen, AM
van't Veer, L
Benitez, J
Casey, G
Peterlin, B
Olah, E
Varley, J
Bignon, YJ
Scherneck, S
Sigurdardottir, V
Lidereau, R
Eyfjord, J
Beckmann, MW
Winqvist, R
Skovlund, E
Borresen-Dale, AL
Citation: K. Laake et al., Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study, GENE CHROM, 25(3), 1999, pp. 212-221
Authors:
Bieche, I
Khodja, A
Lidereau, R
Citation: I. Bieche et al., Deletion mapping of chromosomal region 1p32-pter in primary breast cancer, GENE CHROM, 24(3), 1999, pp. 255-263
Authors:
Bieche, I
Nogues, C
Lidereau, R
Citation: I. Bieche et al., Overexpression of BRCA2 gene in sporadic breast tumours, ONCOGENE, 18(37), 1999, pp. 5232-5238
Authors:
Zeng, WR
Watson, P
Lin, J
Jothy, S
Lidereau, R
Park, M
Nepveu, A
Citation: Wr. Zeng et al., Refined mapping of the region of loss of heterozygosity on the long arm ofchromosome 7 in human breast cancer defines the location of a second tumorsuppressor gene at 7q22 in the region of the CUTL1 gene, ONCOGENE, 18(11), 1999, pp. 2015-2021
Authors:
Tsarfaty, I
Alvord, WG
Resau, JH
Altstock, RT
Lidereau, R
Bieche, I
Bertrand, F
Horev, J
Klabansky, RL
Keydar, I
Vande Woude, GF
Citation: I. Tsarfaty et al., Alteration of Met protooncogene product expression and prognosis in breastcarcinomas, ANAL QUAN C, 21(5), 1999, pp. 397-408